Search - tctmd.com

Displaying 81 - 100 of 303

Sort: Relevancy | Date

News Daily News

TE-PROVE: European Postapproval Study of PES Shows Safety in All-Comers

Yael L. Maxwell

January 28, 2015

News Daily News

TE-PROVE: Estudio Europeo Post-Aprobación de SLP Confirma la Seguridad en Pacientes No Seleccionados

Yael L. Maxwell

January 28, 2015

News Daily News

TE-PROVE：在欧洲开展的PES批准后研究表明该器械在普通人群中是安全的

Yael L. Maxwell

January 28, 2015

News Daily News

Los SLF con Polímero Biodegradable son Seguros y Duraderos al cabo de 5 Años

L.A. McKeown

January 28, 2015

News Features

Las Aprobaciones de los Balones Recubiertos de Fármacos ‘Cambiarán’ el Tratamiento de la EAP

L.A. McKeown

January 28, 2015

News Features

Drug-Coated Balloon Approvals Mark ‘Sea Change’ for Treatment of PAD

L.A. McKeown

January 28, 2015

News Daily News

DES With Biodegradable Polymer Safe, Durable Through 5 Years

L.A. McKeown

January 28, 2015

News Daily News

TCTMD’s Top 10 Most Popular News Stories for 2014

Caitlin E. Cox

January 12, 2015

News Daily News

Retrasar la Cirugía No Cardíaca durante 6 Meses tras la Implantación de un Stent Coronario podría Reducir las Complicaciones

L.A. McKeown

January 12, 2015

News Daily News

Delaying Noncardiac Surgery for 6 Months After Coronary Stenting May Reduce Complications

L.A. McKeown

January 12, 2015

News Industry News

Medtronic Drug-Coated Balloon Receives FDA Approval for Treating Peripheral Artery Disease in Upper Leg

January 04, 2015

News Daily News

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Salynn Boyles

December 15, 2014

Presentation

Stent Coverage and Neointimal Proliferation in BMS Postdilated With a Paclitaxel-Eluting Balloon vs EES

Presenter: T.C. Poerner

December 14, 2014

News Daily News

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

December 14, 2014

News Conference News AHA 2014

Long-Term Better than Short-Term Prasugrel After PES Stenting

November 15, 2014

News Daily News

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

Caitlin E. Cox

October 24, 2014

News Daily News

DCB在原发性病变中的表现比在再狭窄股腘动脉病变中更好

Caitlin E. Cox

October 24, 2014

News Daily News

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Caitlin E. Cox

October 24, 2014

News Industry News

The Lutonix® 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease

October 10, 2014

Presentation TCT 2014

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Freek Nijhoff

September 16, 2014

Advertisement

TE-PROVE: European Postapproval Study of PES Shows Safety in All-Comers

TE-PROVE: Estudio Europeo Post-Aprobación de SLP Confirma la Seguridad en Pacientes No Seleccionados

TE-PROVE：在欧洲开展的PES批准后研究表明该器械在普通人群中是安全的

Los SLF con Polímero Biodegradable son Seguros y Duraderos al cabo de 5 Años

Las Aprobaciones de los Balones Recubiertos de Fármacos ‘Cambiarán’ el Tratamiento de la EAP

Drug-Coated Balloon Approvals Mark ‘Sea Change’ for Treatment of PAD

DES With Biodegradable Polymer Safe, Durable Through 5 Years

TCTMD’s Top 10 Most Popular News Stories for 2014

Retrasar la Cirugía No Cardíaca durante 6 Meses tras la Implantación de un Stent Coronario podría Reducir las Complicaciones

Delaying Noncardiac Surgery for 6 Months After Coronary Stenting May Reduce Complications

Medtronic Drug-Coated Balloon Receives FDA Approval for Treating Peripheral Artery Disease in Upper Leg

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Stent Coverage and Neointimal Proliferation in BMS Postdilated With a Paclitaxel-Eluting Balloon vs EES

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

Long-Term Better than Short-Term Prasugrel After PES Stenting

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

DCB在原发性病变中的表现比在再狭窄股腘动脉病变中更好

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

The Lutonix® 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content